- Home
- GALT vs UDR Comparison
GALT vs UDR Comparison
Compare GALT & UDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- UDR
- Stock Information
- Founded
- GALT 2000
- UDR 1972
- Country
- GALT United States
- UDR United States
- Employees
- GALT N/A
- UDR N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- UDR Real Estate Investment Trusts
- Sector
- GALT Health Care
- UDR Real Estate
- Exchange
- GALT Nasdaq
- UDR Nasdaq
- Market Cap
- GALT 147.8M
- UDR 14.6B
- IPO Year
- GALT N/A
- UDR N/A
- Fundamental
- Price
- GALT $1.04
- UDR $43.67
- Analyst Decision
- GALT Strong Buy
- UDR Buy
- Analyst Count
- GALT 1
- UDR 18
- Target Price
- GALT $11.00
- UDR $44.56
- AVG Volume (30 Days)
- GALT 1.1M
- UDR 1.9M
- Earning Date
- GALT 11-13-2024
- UDR 02-04-2025
- Dividend Yield
- GALT N/A
- UDR 3.91%
- EPS Growth
- GALT N/A
- UDR N/A
- EPS
- GALT N/A
- UDR 0.37
- Revenue
- GALT N/A
- UDR $1,677,719,000.00
- Revenue This Year
- GALT N/A
- UDR N/A
- Revenue Next Year
- GALT N/A
- UDR $0.89
- P/E Ratio
- GALT N/A
- UDR $116.47
- Revenue Growth
- GALT N/A
- UDR 0.06
- 52 Week Low
- GALT $0.73
- UDR $34.19
- 52 Week High
- GALT $4.27
- UDR $47.55
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- UDR 38.33
- Support Level
- GALT $1.80
- UDR $42.33
- Resistance Level
- GALT $2.36
- UDR $45.35
- Average True Range (ATR)
- GALT 0.27
- UDR 0.75
- MACD
- GALT -0.08
- UDR -0.28
- Stochastic Oscillator
- GALT 15.07
- UDR 19.68
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About UDR UDR Inc.
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized prior to January 1, 2021, and held as of December 31, 2022, and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.